Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RYTM Rhythm Pharmaceuticals Inc.

Trading 07-02 13:04:03 EDT

111.94

+1.53

+1.38%

High113.14	Low109.78	Vol330.26K
Open110.79	D1 Closing110.41	Amplitude3.05%
Mkt Cap7.64B	Tradable Cap6.21B	Total Shares68.29M
T/O36.59M	T/O Rate0.60%	Tradable Shares55.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RYTM","market":"US","secType":"STK","nameCN":"Rhythm Pharmaceuticals Inc.","latestPrice":111.935,"timestamp":1783011835547,"preClose":110.41,"halted":0,"volume":330255,"delay":0,"changeRate":0.013812154696132648,"floatShares":55477500,"shares":68285039,"eps":-3.138955,"marketStatus":"Trading","change":1.525,"latestTime":"07-02 13:04:03 EDT","open":110.79,"high":113.14,"low":109.775,"amount":36592389.40455,"amplitude":0.030477,"askPrice":111.94,"askSize":24,"bidPrice":111.66,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-3.138955,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1783022400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1507176000000,"exchange":"NASDAQ","adjPreClose":110.41,"preHourTrading":{"tag":"盘前","latestPrice":110.31,"preClose":110.41,"latestTime":"06:45 EDT","volume":2,"amount":220.62,"timestamp":1782989114587,"change":-0.1,"changeRate":-0.000906,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":110.41,"preClose":110.41,"latestTime":"17:54 EDT","volume":5082,"amount":561110.9,"timestamp":1782942879532,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.485215,"impliedVol":0.5682,"impliedVolPercentile":0.4582},"requestUrl":"/m/hq/s/RYTM","defaultTab":"news","newsList":[{"id":"2648563378","title":"Medicare Coverage Could Put These Obesity Drug Stocks In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2648563378","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648563378?lang=en_us&edition=fundamental","pubTime":"2026-06-30 23:17","pubTimestamp":1782832637,"startTime":"0","endTime":"0","summary":"The obesity and metabolic drug space is suddenly in the spotlight, and not just because of headlines around GLP-1 treatments. A Supreme Court ruling on executive power, Medicare’s move to start covering obesity drugs, and a record close for the Dow are all feeding into a new conversation about where risk and opportunity may sit in this corner of healthcare. This article looks at 3 stocks from our Healthcare Sector, Obesity and Metabolic Drug Manufacturers screener that appear particularly...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/medicare-coverage-could-put-these-obesity-drug-stocks-in-foc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/medicare-coverage-could-put-these-obesity-drug-stocks-in-foc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","PTGX","MDGL","RYTM","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646801925","title":"Rhythm Pharmaceuticals on Track for Highest Close Since January","url":"https://stock-news.laohu8.com/highlight/detail?id=2646801925","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646801925?lang=en_us&edition=fundamental","pubTime":"2026-06-25 23:02","pubTimestamp":1782399720,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals, Inc.  is currently at $109.86, up $2.32 or 2.15%--Would be highest close since Jan. 14, 2026, when it closed at $113.34--On pace for largest percent increase since June 23, 2026, when it rose 4.73%--Currently up 11 of the past 12 days--Currently up 10 consecutive days; up 28.18% over this period--Longest winning streak on record --Best 10 day stretch since the 10 days ending July 22, 2025, when it rose 34.82%--Up 24.39% month-to-date--Up 2.64% year-to-date--Down 6.59% from its all-time closing high of $117.62 on Dec. 11, 2025--Up 78.8% from 52 weeks ago , when it closed at $61.45--Down 6.59% from its 52-week closing high of $117.62 on Dec. 11, 2025--Up 78.8% from its 52-week closing low of $61.45 on June 26, 2025--Traded as high as $111.71; highest intraday level since Jan. 15, 2026, when it hit $114.00--Up 3.87% at today's intraday highAll data as of 10:59:15 AM ETSource: Dow Jones Market Data, FactSet Dow Jones NewswiresJune 25, 2026 11:02 ET Copyright  2026 D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646845949","title":"Rhythm Pharma Director Lynn A. Tetrault Disposes of Common Shares Worth $3.71 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2646845949","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646845949?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:16","pubTimestamp":1782332214,"startTime":"0","endTime":"0","summary":"Rhythm Pharma director Lynn A. Tetrault disposes of common shares worth $3.71 millionRhythm Pharmaceuticals director Lynn A. Tetrault exercised stock options for 37,000 common shares at USD 28.27 on J","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL8MyTgc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rhythm Pharma Director Lynn A. Tetrault Disposes of Common Shares Worth $3.71 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RYTM","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029043","title":"Rhythm Pharmaceuticals (RYTM) Stock Could Be 30.6% Undervalued on Its Growth Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029043","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029043?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:21","pubTimestamp":1782123715,"startTime":"0","endTime":"0","summary":"Recent Share Performance and Business Context\nRhythm Pharmaceuticals (RYTM) has drawn investor attention after recent share price moves, with the stock last closing at $96.79 and showing positive total returns over the past month and past 3 months.\nThe Boston based biopharmaceutical company focuses on rare neuroendocrine diseases, with revenue of $217.17 million and an annual revenue growth figure of 38.46%, alongside a reported net loss of $207.84 million.\nSee our latest analysis for Rhythm...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-stock-could-be-306-undervalued-o","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-stock-could-be-306-undervalued-o","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4588","RYTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644971006","title":"Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Rhythm Pharmaceuticals (RYTM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644971006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644971006?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:30","pubTimestamp":1781692210,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dianthus Therapeutics (DNTH) and Rhythm Pharmaceutic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-and-rhythm-pharmaceuticals-rytm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-and-rhythm-pharmaceuticals-rytm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0128526141.USD","XLV","LABU","XBI","LU0029874061.USD","HCSG","DNTH","BK4137","RYTM","BK4581","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644876679","title":"Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2644876679","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644876679?lang=en_us&edition=fundamental","pubTime":"2026-06-17 00:03","pubTimestamp":1781625780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2026 12:03 ET (16:03 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643736627","title":"Rhythm Pharmaceuticals Inc : Canaccord Genuity Raises Target Price to $151 From $143","url":"https://stock-news.laohu8.com/highlight/detail?id=2643736627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643736627?lang=en_us&edition=fundamental","pubTime":"2026-06-16 13:44","pubTimestamp":1781588651,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nFWN42N0MZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BK4139","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643853887","title":"BRIEF-Rhythm Pharmaceuticals Announces Multiple New Data Presentations From Mc4r Agonists","url":"https://stock-news.laohu8.com/highlight/detail?id=2643853887","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643853887?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:02","pubTimestamp":1781553726,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Pharmaceuticals Announces Multiple New Data Presentations From Mc4r Agonists June 15 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:RHYTHM PHARMACEUTICALS ANNOUNCES MULTIPLE NEW DATA PRESE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA3JNLFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643858097","title":"Rhythm Pharma says setmelanotide cuts BMI 18.9% at 2.5 years in hypothalamic obesity study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643858097","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643858097?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:01","pubTimestamp":1781553685,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals flagged new clinical updates on its MC4R agonists at ENDO 2026, with results already presented during the meeting.Setmelanotide showed durable weight loss over long-term follow-up in acquired hypothalamic obesity, supporting its potential as a chronic therapy option.Oral bivamelagon produced continued improvements in weight and patient-reported hunger over one year in acquired hypothalamic obesity, reinforcing its oral development strategy.Real-world analyses in Bardet-Biedl syndrome indicated meaningful weight-related benefits with setmelanotide, alongside lower obesity-related outpatient utilization.Additional ENDO posters pointed to benefits in acquired hypothalamic obesity subgroups, including patients with prior bariatric surgery, with separate positive data referenced in Prader-Willi syndrome.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDLb6bjsd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","BK4585","IE00BKPKM429.USD","NDAQ","BK4588","SG9999014005.SGD","RYTM","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4112","SG9999014021.USD","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014039.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643858437","title":"Rhythm Pharmaceuticals Announces Multiple New Data Presentations From Mc4r Agonists in Acquired Hypothalamic Obesity (Ho), Bardet-Biedl Syndrome (Bbs) and Prader-Willi Syndrome (Pws) at Endo 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643858437","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643858437?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:01","pubTimestamp":1781553660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA3JNLFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","BK4139","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643201734","title":"Rhythm Pharmaceuticals (RYTM) Receives a Buy from Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2643201734","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643201734?lang=en_us&edition=fundamental","pubTime":"2026-06-15 22:17","pubTimestamp":1781533072,"startTime":"0","endTime":"0","summary":"Jefferies analyst Dennis Ding maintained a Buy rating on Rhythm Pharmaceuticals today and set a price target of $125.00. According to TipRanks, Din...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rhythm-pharmaceuticals-rytm-receives-a-buy-from-jefferies-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rhythm-pharmaceuticals-rytm-receives-a-buy-from-jefferies-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643270086","title":"Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Rhythm Pharmaceuticals (RYTM) and Belite Bio, Inc. ADR (BLTE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643270086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643270086?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:10","pubTimestamp":1781521813,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inventiva (IVA), Rhythm Pharmaceuticals (RYTM) and B...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-rhythm-pharmaceuticals-rytm-and-belite-bio-inc-adr-blte-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-rhythm-pharmaceuticals-rytm-and-belite-bio-inc-adr-blte-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4139","XLV","BLTE","LU0128526141.USD","RYTM","BK4585","BK4137","XBI","HCSG","IVA","LABU","LU0029874061.USD","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643498247","title":"Rhythm announces preliminary data from Phase 2 trial of setmelanotide","url":"https://stock-news.laohu8.com/highlight/detail?id=2643498247","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643498247?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:35","pubTimestamp":1781469333,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) announced preliminary data from a Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome deliv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rhythm-announces-preliminary-data-from-phase-2-trial-of-setmelanotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rhythm-announces-preliminary-data-from-phase-2-trial-of-setmelanotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RYTM","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643024272","title":"Rhythm Pharmaceuticals (RYTM) Stock After Positive Phase 2 PWS Data What Does The Valuation Suggest","url":"https://stock-news.laohu8.com/highlight/detail?id=2643024272","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643024272?lang=en_us&edition=fundamental","pubTime":"2026-06-15 02:13","pubTimestamp":1781460825,"startTime":"0","endTime":"0","summary":"Phase 2 PWS data and what it could mean for Rhythm Pharmaceuticals stock\nRhythm Pharmaceuticals (RYTM) recently reported six month interim Phase 2 data for setmelanotide in Prader Willi syndrome, highlighting clinically meaningful changes in BMI, fat mass, hyperphagia, and anxiety, and outlined plans to move into Phase 3 development.\nSee our latest analysis for Rhythm Pharmaceuticals.\nThe latest PWS data arrives after a mixed share price stretch, with the stock down 15.84% year to date on a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-stock-after-positive-phase-2-pws","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-stock-after-positive-phase-2-pws","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4588","RYTM","BK4139","PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643214107","title":"BRIEF-Rhythm Pharmaceuticals Says Six-Month Data Shows Setmelanotide Improves Multiple Endpoints In Pws","url":"https://stock-news.laohu8.com/highlight/detail?id=2643214107","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643214107?lang=en_us&edition=fundamental","pubTime":"2026-06-13 20:06","pubTimestamp":1781352404,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Pharmaceuticals Says Six-Month Data Shows Setmelanotide Improves Multiple Endpoints In Pws June 13 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:RHYTHM PHARMACEUTICALS PRESENTS POSITIVE I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260613:nTUABKCRP5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643141792","title":"Rhythm Pharmaceuticals - Six-Month Data Shows Setmelanotide Improves Multiple Endpoints in Pws as of May 7, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643141792","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643141792?lang=en_us&edition=fundamental","pubTime":"2026-06-13 20:01","pubTimestamp":1781352060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260613:nTUABKCRP5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","RYTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643220290","title":"Rhythm Pharma to present interim six-month Phase 2 setmelanotide data in Prader-Willi syndrome on June 13","url":"https://stock-news.laohu8.com/highlight/detail?id=2643220290","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643220290?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:01","pubTimestamp":1781294484,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals scheduled a June 13 conference call to present interim six-month Phase 2 results for setmelanotide in Prader-Willi syndrome.Data will be presented in the future; no clinical outcomes were disclosed in the announcement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL9nNj24:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4588","SG9999014013.SGD","BK4112","SG9999014021.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","SG9999014039.USD","NDAQ","RYTM","LU2095319765.USD","BK4585","IE00BN0W2T93.GBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643429021","title":"Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients With Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2643429021","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643429021?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:01","pubTimestamp":1781294460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nTUA1S4QGP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","RYTM","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639460315","title":"Rhythm Algorithm Aims To Clarify Bardet Biedl Diagnosis And Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2639460315","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639460315?lang=en_us&edition=fundamental","pubTime":"2026-05-30 09:05","pubTimestamp":1780103146,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (NasdaqGM:RYTM) has published a new evidence-based diagnostic algorithm for Bardet-Biedl syndrome.\nThe algorithm is designed to streamline and accelerate clinical diagnosis of this rare obesity disorder.\nThe update incorporates recent advances in genetic testing to support earlier and more accurate identification of BBS.\n\nRhythm Pharmaceuticals focuses on treatments for rare genetic forms of obesity, and Bardet-Biedl syndrome is a core part of that remit. A clearer...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-algorithm-aims-to-clarify-bardet-biedl-diagnosis-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-algorithm-aims-to-clarify-bardet-biedl-diagnosis-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4588","RYTM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638169878","title":"Rhythm Pharma hosts inaugural MOMENTUM MC4R Pathway Summit featuring updated BBS diagnostic algorithm presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2638169878","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638169878?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:07","pubTimestamp":1779970061,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals will host its inaugural MOMENTUM MC4R Pathway Summit on June 12 in Chicago.Brooke Sweeney, MD, will present an updated Bardet-Biedl syndrome diagnostic algorithm at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL7cWZhP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rhythmtx.com","stockEarnings":[{"period":"1week","weight":0.0266},{"period":"1month","weight":0.2565},{"period":"3month","weight":0.2795},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.6872},{"period":"ytd","weight":0.0315}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051908},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.048958},{"month":3,"riseRate":0.111111,"avgChangeRate":-0.056668},{"month":4,"riseRate":0.555556,"avgChangeRate":0.013671},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045608},{"month":6,"riseRate":0.555556,"avgChangeRate":0.069919},{"month":7,"riseRate":0.444444,"avgChangeRate":0.249805},{"month":8,"riseRate":0.75,"avgChangeRate":0.239414},{"month":9,"riseRate":0.375,"avgChangeRate":-0.040591},{"month":10,"riseRate":0.375,"avgChangeRate":-0.015139},{"month":11,"riseRate":0.777778,"avgChangeRate":0.136999},{"month":12,"riseRate":0.555556,"avgChangeRate":0.041318}],"exchange":"NASDAQ","name":"Rhythm Pharmaceuticals Inc.","nameEN":"Rhythm Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rhythm Pharmaceuticals Inc.,RYTM,Rhythm Pharmaceuticals Inc.股票,Rhythm Pharmaceuticals Inc.股票老虎,Rhythm Pharmaceuticals Inc.股票老虎国际,Rhythm Pharmaceuticals Inc.行情,Rhythm Pharmaceuticals Inc.股票行情,Rhythm Pharmaceuticals Inc.股价,Rhythm Pharmaceuticals Inc.股市,Rhythm Pharmaceuticals Inc.股票价格,Rhythm Pharmaceuticals Inc.股票交易,Rhythm Pharmaceuticals Inc.股票购买,Rhythm Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction